市场调查报告书
商品编码
1276313
全球肠道疾病检测市场规模,份额,行业趋势分析报告:按最终用户,按疾病类型,按产品类型(试剂/耗材,设备),按检测方法,地区,展望/预测,2023-2029年Global Enteric Disease Testing Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type, By Product Type (Reagents & Consumables and Equipment), By Technique, By Regional Outlook and Forecast, 2023 - 2029 |
在预测期内,肠道疾病检测市场规模预计将以 3.2% 的复合年增长率增长,到 2029 年将达到 46 亿美元。
肠道疾病是由影响肠道的细菌、病毒和寄生生物引起的。 这些疾病中有许多可以在人与人之间传播,通常是由食用受污染的食物或饮料引起的。 肠道感染的症状包括噁心、腹痛、发冷、发烧、腹泻和食慾不振。
已发现肠道细菌是许多水源性疾病和食源性疾病的主要原因。 腹泻和溶血性尿毒症综合征 (HUS) 在世界范围内变得越来越普遍。 肠道细菌感染是最常见的原因。 由于腹泻发病率上升、新兴国家发病率上升、政府意识提高以及政府和公共机构的各种举措等因素,预计在整个预测期内,肠道细菌性疾病检测市场将扩大。
COVID-19 影响分析
由于大流行影响了医疗保健优先事项,因此 COVID-19 检测和治疗优先于肠道疾病检测。 COVID-19 大流行需要大量资源重新分配给 COVID-19 检测、治疗和疫苗接种工作。 因此,资源已从其他医疗保健领域转移,例如肠道疾病检测。 这是由多种因素共同造成的,包括医疗保健能力下降和社会疏远做法。 COVID-19 疫情扰乱了许多关于肠道疾病的研究项目,并将资源转移到 COVID-19 研究上。 大流行期间对肠道疾病检测试剂盒的需求减少对市场增长产生了负面影响。
市场增长因素
全球肠道疾病患病率不断上升
这些检测也证明了艰难梭菌、志贺氏菌、大肠桿菌、霍乱和沙门氏菌病等肠道疾病的流行率不断上升,这些疾病可导致严重腹泻甚至死亡。 肠道感染每年影响全球数百万人,尤其是在卫生条件差的欠发达国家。 因此,预计肠道疾病患病率上升将在整个预测期内推动市场增长。
通过积极的研发增加技术突破
肠病检测的需求可能受益于肠病检测设备和检测方法的技术发展和改进。 改进的测试效率、具有成本效益的测试和更快的测试结果有助于产品开发。 此外,医疗保健企业越来越多地连接到更高效、更有效且价格更实惠的计算硬件,这些硬件具有增强的网络连接、改进的软件和先进的传感器。 因此,未来几年市场可能会从这些变量中获益。
市场製约因素
测试和采样成本高
由于具有先进的功能和特点,自动肠道疾病检测仪器的价格高于手动检测仪器。 当您将介质、设备和人工成本考虑在内时,对于某些最终用户来说,这似乎贵得令人望而却步。 此外,在实验室中部署大量系统会显着增加总资本成本投资。 分子诊断技术的利用,尤其是与单重检测相比的多重检测,是医疗保健行业的最新发展。 然而,多重检测设备的成本相对较高,安装设备所需的初始投资也很高。 在成本效益高的替代品出现之前,这一因素将阻碍市场增长。
产品类型展望
按产品类型划分,肠道疾病检测市场分为试剂/耗材和仪器。 2022年肠道疾病检测市场,器械板块实现大幅增长。 在此过程中使用了不同类型的肠道疾病测试,推动了这一细分市场的增长。 自动分析仪用于对肠道疾病进行快速检测。 这些测试可以检测样品中病原体的特定抗原或遗传物质的存在。
检验方法展望
肠道疾病检测市场按检测方法分为分子诊断和免疫诊断。 免疫诊断部门将在 2022 年占据肠道疾病检测市场最大的收入份额。 免疫诊断测试可在短短几个小时内得出结果,使肠道疾病的早期诊断和治疗成为可能。 免疫诊断测试甚至可以检测到少量的病原体和抗体,使其成为高度敏感和特异的测试。 这意味着您可以查明特定病原体的存在并排除导致患者症状的其他可能性。
按疾病类型划分的前景
肠道疾病检测市场按疾病类型分为三类:细菌、病毒和寄生虫。 沙门氏菌病、霍乱、大肠桿菌和幽门螺桿菌等细菌性肠病的高流行以及用于诊断的肠道疾病检测产品的广泛使用正在推动这一细分市场的增长。 由于对细菌性肠病诊断知识的提高和全球细菌性肠病发病率的上升,预计该类别也将经历快速增长。
最终用户视角
按最终用户划分,肠道疾病检测市场分为学术和研究机构、医院实验室以及製药和生物技术公司。 2022 年,学术和研究机构部门在肠道疾病检测市场中占据了相当大的收入份额。 学术和研究机构在肠道疾病的公共卫生监测中发挥着重要作用。 对人群中的肠道疾病进行检测和监测有助于确定疫情、制定应对计划以及实施预防和控制策略。 研究实验室在识别引起肠道疾病的新病原体方面发挥着重要作用。
区域展望
按地区划分,对北美、欧洲、亚太地区和拉美地区的肠道疾病检测市场进行了分析。 2022 年,北美市场在肠道疾病检测市场的收入份额最大。 该地区许多重要参与者的存在,以及肠道疾病检测产品製造技术的改进,正在推动市场的扩张。 这主要是由于肠道疾病患者增加,政府加大对肠道疾病诊断研究的支持力度,以及发达国家资本收入的显着增加。
市场进入者采取的主要策略是收购。 根据基数矩阵中的分析,Thermo Fisher Scientific, Inc. 是肠道疾病检测市场的先行者。 Neogen Corporation、Bureau Veritas S.A. 和 Eurofins Scientific SE 等公司是肠道疾病检测市场的领先创新者。
The Global Enteric Disease Testing Market size is expected to reach $4.6 billion by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
Infections of the gastrointestinal tract, encompassing the small intestine, large intestine, and stomach, are known as enteric diseases. Bacteria, viruses, and parasites are just a few of the microorganisms that might cause these diseases. Salmonellosis, shigellosis, norovirus, rotavirus, amebiasis, cryptosporidiosis, and giardiasis are typical examples of enteric diseases. Others include cholera, Clostridium difficile (C. difficile), Escherichia coli (E. coli), shigellosis, and Helicobacter pylori (H. pylori).
To determine the exact pathogen triggering an enteric disease and to diagnose enteric diseases, numerous laboratory tests are employed. These tests often entail checking samples of blood, feces, or other fluids from the body for the presence of viruses, bacteria, and parasites known as enteric pathogens.
Enteric disorders are caused by bacterial, viral, and parasitic microorganisms that affect the intestines. Many of these illnesses can be spread from person to person and are typically brought on by consuming tainted food or drink. The symptoms of enteric infections include nausea, stomach pain, chills, fever, diarrhea, and loss of appetite.
One of the primary agents behind many water- and food-borne illnesses has been shown to be enteric bacteria. Diarrhea and hemolytic uremic syndrome (HUS) are becoming more common worldwide. Enteric bacterial infections are the most frequent cause. The enteric disease testing market is expected to expand throughout the forecast period due to factors such as rising rates of diarrhea, rising rates in emerging nations, higher government awareness, and various government and public sector initiatives.
COVID-19 Impact Analysis
COVID-19 testing and treatment took precedence over enteric illness testing as a result of the pandemic's impact on healthcare priorities. The COVID-19 pandemic required a massive redirection of resources towards COVID-19 testing, treatment, and vaccination efforts. This led to a diversion of resources away from other areas of healthcare, including enteric disease testing. This was due to a combination of factors, including reduced healthcare capacity, and social distancing measures. The COVID-19 pandemic disrupted many research projects related to enteric diseases, with resources and personnel being diverted towards COVID-19 research. The demand for enteric disease testing kits decreased during the pandemic, which negatively impacted market growth.
Market Growth Factors
Increasing prevalence of enteric disease worldwide
The rise in the prevalence of several other enteric diseases such as clostridium difficile (C. difficile), shigellosis, Escherichia coli (E. coli), cholera, and salmonellosis-all of which can result in severe diarrhea or even death-also contributes to the increasing demand for these tests. Rising Millions of people contract enteric infections every year worldwide, but they are particularly prevalent in underdeveloped nations with subpar sanitation. Hence, the rising prevalence of enteric disease will propel the growth of the market throughout the forecast period.
Rising number of technological breakthroughs owing to increased R&D
The demand for enteric disease testing may benefit from the growing technological developments and improvements in enteric disease testing equipment and methods. Testing efficiency gains, cost-effective testing, and quick test results may contribute to product development. Additionally, the healthcare business is embracing the growing trend of more efficient, effective, and affordable computing hardware connected to greater network connectivity, improved software, and advanced sensors. In light of this, the market may benefit financially from these variables in the years to come.
Market Restraining Factors
High cost of testing and sampling
Automated enteric disease testing instruments are priced higher than their manual counterparts due to their advanced features and functions. The calculated cost of the media, instrument, and labor may be perceived as prohibitively expensive by certain end users. In addition, implementing numerous systems in testing laboratories has significantly increased the total capital cost investment. Utilizing molecular diagnostic techniques, particularly multiplexed assays, is a recent development in the healthcare industry compared to singleplex assays. However, the cost of multiplexed assay equipment is comparatively high, and the initial investment required for instrument installation is higher. This factor will impede the market's growth until cost-effective alternatives become available.
Product Type Outlook
Based on product type, the enteric disease testing market is characterized into reagents & consumables and equipment. The equipment segment procured a considerable growth rate in the enteric disease testing market in 2022. Different types of enteric disease testing are used in the process, which is propelling the growth of the segment. Automated analyzers are used to perform rapid tests for enteric diseases. These tests can detect the presence of specific antigens or genetic material from the pathogen in a sample.
Technique Outlook
On the basis of technique, the enteric disease testing market is classified into molecular diagnostics and immunodiagnostics. The immunodiagnostics segment acquired the largest revenue share in the enteric disease testing market in 2022. Immunodiagnostic tests can provide results quickly, sometimes in as little as a few hours, which allows for earlier diagnosis and treatment of enteric diseases. Immunodiagnostic tests can detect even small amounts of pathogens or antibodies, making them highly sensitive and specific. This means they can accurately identify the presence of a specific pathogen and rule out other potential causes of the patient's symptoms.
Disease Type Outlook
By disease type, the enteric disease testing market is divided into bacterial, viral, and parasitic. The high prevalence of bacterial enteric diseases such as salmonellosis, cholera, E. coli, and Helicobacter pylori, as well as the widespread utilization of enteric disease testing products for the diagnosis, are driving the growth of this market segment. In addition, due to increased knowledge of bacterial enteric disease diagnosis and a rising incidence of bacterial enteric diseases globally, the category is anticipated to experience rapid growth.
End User Outlook
Based on end user, the enteric disease testing market is segmented into academic & research institutes, hospital laboratories, and pharmaceutical & biotechnology companies. The academic & research institutes segment acquired a substantial revenue share in the enteric disease testing market in 2022. Academic and research institutes play a vital role in public health surveillance for enteric diseases. Testing and monitoring of enteric diseases in populations can help in identifying outbreaks, developing response plans, and implementing prevention and control strategies. Research institutes play a crucial role in identifying new pathogens responsible for enteric diseases.
Regional Outlook
Region wise, the enteric disease testing market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the enteric disease testing market in 2022. The presence of a number of significant players as well as improvements in the manufacturing technology of enteric disease testing products in the region is what is driving the market's expansion. This is mostly due to an increase in the number of patients with enteric diseases, increased government support for research into the diagnosis of enteric diseases, and a sizable increase in capital income in industrialized nations.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the Enteric Disease Testing Market. Companies such as Neogen Corporation, Bureau Veritas S.A., and Eurofins Scientific SE are some of the key innovators in Enteric Disease Testing Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TUV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
Recent Strategies Deployed in Enteric Disease Testing Market
Mergers and Acquisitions:
Jan-2023: Thermo Fisher Scientific Inc. took over The Binding Site Group, a global leader in specialty diagnostics. Through this acquisition, Thermo Fisher Scientific Inc. would be able to extend its current specialty diagnostics portfolio along with pioneering innovation in monitoring and diagnostics for numerous myelomas.
Sep-2022: Bureau Veritas took over Galbraith Laboratories, a US-based operator of contract analytical testing. The addition of Galbraith expands the acquiring company's market presence in the personal care, industrial, and consumer healthcare markets, and further expands Bureau Veritas' market position in the North American region.
Sep-2022: Neogen announced the completion of a merger with 3M's Food Safety business. 3M's food safety business is merged with Neogen. The combination expands the merged company's geographical footprint, digitization capabilities, etc.
Jul-2022: Neogen completed the acquisition of Thai-Neo Biotech, a Thailand-based distributor of food safety products. The acquisition enables the acquiring company to establish a direct presence in Thailand and the Southeast Asian region. Further, the addition of Thai-Neo Biotech perfectly complements Neogen's operations in China, Australia, and India.
Jun-2022: Eurofins acquired a majority stake in Ajal for Laboratories, a Saudi Arabia-based provider of laboratory services. This acquisition broadens the acquiring company's food and pharmaceutical product test offerings in Saudi Arabia. Further, the acquisition reflects Eurofins' commitment to developing a local and regional laboratory network across the whole Middle East.
Sep-2021: Neogen acquired CAPInnoVet, a US-based provider of animal health medicines and products. This acquisition provides Neogen entry to the retail parasiticide market. The acquired company will be a part of Neogen's Animal Safety business segment.
Apr-2021: Thermo Fisher Scientific Inc. took over PPD, Inc., a pharmaceutical company engaged in clinical research. Through this acquisition, the company would provide a vast range of services in the clinical development spectrum. This includes the development and manufacturing of the drug product, healthcare outcomes, trial logistics., scientific discovery, etc.
Partnerships, Collaborations and Agreements:
Oct-2022: Thermo Fisher Scientific came into partnership with Genoox, a provider of fast and accurate tools to solve complex, genomic data challenges, delivering advanced, and end-to-end genomic analysis tools. The partnership aims to automate the interpretation and reporting of cytogenetic research data with AI. ChAS users can access Franklin, Genoox's cloud-based AI platform with the launch of CytoScan Automated Interpretation and Reporting (AIR) solution for making cytogenetic research data analysis easy.
Apr-2022: SGS came into partnership with Liveome, a South Korea-based operator of microbiome research-based firm. The partnership focuses on the development and commercialization of LIV001, an inflammatory bowel disease (IBD) candidate. The partnership demonstrates SGS' ability to provide its services globally.
Product Launches and Expansions:
Dec-2022: Thermo Fisher introduced TrueMark Infectious Disease Research Panels, developed to enable quick and precise detection and categorization for investigating microorganisms. The new panel are real-time polymerase chain reaction (PCR) syndromic panels and gives an option to the user to choose between standard or custom panels.
Oct-2022: Thermo Fisher launched TaqPath Enteric Bacterial Select Panel, a CE-IVD marked test intended for common Gastrointestinal bacteria. The new test detects gastrointestinal (GI) bacteria and speeds up the root cause identification process. The GI bacteria detecting test is based on polymerase chain reaction (PCR) technology to examine the stool samples. The test can deliver results with 98% specificity, and sensitivity within two hours.
Market Segments covered in the Report:
By End User
By Disease Type
By Product Type
By Technique
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures